Sugi Predict

Sugi Predict / Compounds / SCHEMBL3997516

SCHEMBL3997516

SCHEMBL3997516

C=CCOC(=O)N1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ ALDH1A1 P00352 7/20 0.41
▸ POLB P06746 2/20 0.41
▸ ERN1 O75460 2/20 0.40
▸ THRB P10828 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ GPR119 Q8TDV5 1/20 0.37
▸ HSD11B1 P28845 1/20 0.37
▸ GAA P10253 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ HTT P42858 2/20 0.36
▸ SLC6A15 Q9H2J7 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3992214 1.00 LMNA (0.45) LMNAMAPK1RAB9AALDH1A1POLB
SCHEMBL4195614 0.98 LMNA (0.46) LMNAMAPK1RAB9AALDH1A1POLB
SCHEMBL30592964 0.83 CA2 (0.42) LMNAMAPK1RAB9AERN1GPR119
SCHEMBL27483615 0.82 ALDH1A1 (0.42) LMNAALDH1A1POLBTHRBATM
SCHEMBL1780077 0.81 LMNA (0.43) LMNAMAPK1RAB9AALDH1A1POLB
SCHEMBL21445983 0.81 ALDH1A1 (0.38) LMNAMAPK1RAB9AALDH1A1POLB
SCHEMBL8665411 0.81 TSHR (0.59) LMNAMAPK1RAB9AALDH1A1POLB
SCHEMBL9342278 0.81 MAPK1 (0.46) LMNAMAPK1RAB9AALDH1A1POLB
SCHEMBL2985134 0.81 LMNA (0.46) LMNAMAPK1RAB9AALDH1A1POLB
SCHEMBL4613656 0.81 LMNA (0.43) LMNAMAPK1RAB9AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116783160-A Libraries of compounds 中外制药株式会社 2023-09-19 — — CN disclosed
US-11081729-B2 Non-aqueous electrolyte solution additive, and non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery which include the same LG CHEM, LTD. 2021-08-03 — — US disclosed
EP-3518334-B1 NON-AQUEOUS ELECTROLYTE SOLUTION ADDITIVE, NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAID ADDITIVE LG CHEMICAL LTD (KR) 2021-04-21 — — EP disclosed
US-20200044287-A1 Non-aqueous Electrolyte Solution Additive, and Non-aqueous Electrolyte Solution for Lithium Secondary Battery and Lithium Secondary Battery which Include the Same LG CHEM, LTD. (KR) 2020-02-06 — — US disclosed
CN-110036004-A Inhibitors of cyclin dependent kinase 7(CDK7) 希洛斯医药品股份有限公司 2019-07-19 — — CN disclosed
CN-107847765-A The piperidine derivative of 1,4 substitutions 赛福伦公司 2018-03-27 — — CN disclosed
US-9657030-B2 Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof RHODES TECHNOLOGIES (US) 2017-05-23 — — US disclosed
US-9657030-B2 Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof RHODES TECHNOLOGIES (US) 2017-05-23 — — US disclosed
US-9624232-B2 Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof RHODES TECHNOLOGIES (US) 2017-04-18 — — US disclosed
US-9624232-B2 Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof RHODES TECHNOLOGIES (US) 2017-04-18 — — US disclosed
CN-101641330-A Benzamide derivatives and process for preparing the same DONG A PHARM CO LTD KR 2010-02-03 — — CN disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 — — US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 — — EP disclosed
WO-2008025857-A2 NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES TOPOTARGET SWITZERLAND SA (CH) 2008-03-06 — — WO disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 — — WO disclosed
CN-1304391-C Preparation method of hydrobromic acid antifebrile dichroanone SHANGHAI YINNUO BIOCHEMICAL SC (CN) 2007-03-14 — — CN disclosed
CN-1651428-A Preparation method of hydrobromic acid antifebrile dichroanone SHANGHAI YINNUO BIOCHEMICAL SC (CN) 2005-08-10 — — CN disclosed
CN-1060778-C Cephalosporin derivatives HOFFMANN LA ROCHE (CH) 2001-01-17 — — CN disclosed
US-6156889-A Reagent useful for cleaving a protected functional group RHODIA CHIMIE (FR) 2000-12-05 — — US disclosed
US-5847117-A Reagent and catalytic process useful for cleaving a protected functional group RHONE-POULENC CHIMIE (FR) 1998-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200044287-A1 Non-aqueous Electrolyte Solution Additive, and Non-aqueous Electrolyte Solution for Lithium Secondary Battery and Lithium Secondary Battery which Include the Same LAGE3, KCNN2, CACNA1F LMNA 229/4885MAPK1 2698/4885RAB9A 65/4885
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC LMNA 4825/4885MAPK1 624/4885RAB9A 3949/4885
US-11081729-B2 Non-aqueous electrolyte solution additive, and non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery which include the same LAGE3, KCNN2, CACNA1F LMNA 229/4885MAPK1 2698/4885RAB9A 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.